{"DataElement":{"publicId":"11334663","version":"1","preferredName":"Disease or Disorder European LeukemiaNet Risk Classification Core Binding Factor Type","preferredDefinition":"A response to disease or disorder of guidelines developed by the European LeukemiaNet group to optimize the selection of acute myeloid leukemia therapy based on a subject's genetic profile is present and to verify the type of cytogenetic abnormalities result in disruption of the transcription factor CBF.","longName":"11334657v1.00:11332303v1.00","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"11334657","version":"1","preferredName":"Disease or Disorder European LeukemiaNet Risk Classification","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:A guideline developed by the European LeukemiaNet group to optimize the selection of acute myeloid leukemia therapy based on a subject's genetic profile.","longName":"11334656v1.00:2233878v1.00","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"11334665","version":"1","preferredName":"European LeukemiaNet Risk Classification","preferredDefinition":"A guideline developed by the European LeukemiaNet group to optimize the selection of acute myeloid leukemia therapy based on a subject's genetic profile.","longName":"C177562","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"European LeukemiaNet Risk Classification","conceptCode":"C177562","definition":"A guideline developed by the European LeukemiaNet group to optimize the selection of acute myeloid leukemia therapy based on a subject's genetic profile.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D49492-0317-5405-E053-731AD00AA22D","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D25406-731D-1190-E053-731AD00AC5B6","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"11332303","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia Type","preferredDefinition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis._Something distinguishable as an identifiable class based on common qualities.","longName":"11332303v1.00","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"0","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CBF AML","valueDescription":null,"ValueMeaning":{"publicId":"11332304","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia","longName":"11332304v1.00","preferredDefinition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D1F9DE-1618-7CB6-E053-731AD00AB956","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D1F9DE-161A-7CB6-E053-731AD00AB956","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"},{"value":"Non-CBF AML","valueDescription":null,"ValueMeaning":{"publicId":"11332305","version":"1","preferredName":"Negation Core Binding Factor Acute Myeloid Leukemia","longName":"11332305v1.00","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction._Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D1F9DE-1619-7CB6-E053-731AD00AB956","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D1F9DE-161B-7CB6-E053-731AD00AB956","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"},{"value":"Non-CBF, good/intermediate","valueDescription":null,"ValueMeaning":{"publicId":"11334659","version":"1","preferredName":"Good Intermediate Risk Negation Core Binding Factor Acute Myeloid Leukemia","longName":"11334659v1.00","preferredDefinition":"Valuable or useful or agreeable or pleasing._The potential future harm that may arise from some present action or attribute or condition is moderate._An operation in which a term denies or inverts the meaning of another term or construction._Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Good","conceptCode":"C64975","definition":"Valuable or useful or agreeable or pleasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Intermediate Risk","conceptCode":"C102402","definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D28F3D-54E4-1814-E053-731AD00A23E5","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"KUMMEROA","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D28F3D-54E7-1814-E053-731AD00A23E5","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"},{"value":"Non-CBF, high risk","valueDescription":null,"ValueMeaning":{"publicId":"11334660","version":"1","preferredName":"High Risk Acute Leukemia Negation Core Binding Factor Acute Myeloid Leukemia","longName":"11334660v1.00","preferredDefinition":"Acute leukemia patients are stratified into the high risk group when their minimal residual disease levels are higher than 0.05%._An operation in which a term denies or inverts the meaning of another term or construction._Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Risk Acute Leukemia","conceptCode":"C122458","definition":"Acute leukemia patients are stratified into the high risk group when their minimal residual disease levels are higher than 0.05%.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D28F3D-54E5-1814-E053-731AD00A23E5","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D28F3D-54E8-1814-E053-731AD00A23E5","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"},{"value":"Not applicable, CBF","valueDescription":null,"ValueMeaning":{"publicId":"11334661","version":"1","preferredName":"Not Applicable Core Binding Factor Acute Myeloid Leukemia","longName":"11334661v1.00","preferredDefinition":"Determination of a value is not relevant in the current context._Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D28F3D-54E6-1814-E053-731AD00A23E5","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9D28F3D-54E9-1814-E053-731AD00A23E5","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"11332302","version":"1","preferredName":"Core Binding Factor Acute Myeloid Leukemia Type","preferredDefinition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis._Something distinguishable as an identifiable class based on common qualities.","longName":"11332302v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Core Binding Factor Acute Myeloid Leukemia","conceptCode":"C122688","definition":"Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D1ECA7-216B-7B2D-E053-731AD00A3C0E","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2022-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D1ECA7-216C-7B2D-E053-731AD00A3C0E","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"ELN Risk Group","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9D2CCDE-AD8E-1F50-E053-731AD00A679F","latestVersionIndicator":"Yes","beginDate":"2022-09-29","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-09-29","modifiedBy":"SOKKERL","dateModified":"2023-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}